These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 30681751

  • 1. Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: A nationwide study.
    Lin CW, Huang WI, Chao PH, Chen WW, Hsiao FY.
    Int J Clin Pract; 2019 May; 73(5):e13316. PubMed ID: 30681751
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.
    Bardin T, Chalès G, Pascart T, Flipo RM, Korng Ea H, Roujeau JC, Delayen A, Clerson P.
    Joint Bone Spine; 2016 May; 83(3):314-7. PubMed ID: 26709250
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
    Ju C, Lai RWC, Li KHC, Hung JKF, Lai JCL, Ho J, Liu Y, Tsoi MF, Liu T, Cheung BMY, Wong ICK, Tam LS, Tse G.
    Rheumatology (Oxford); 2020 Sep 01; 59(9):2340-2349. PubMed ID: 31873735
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
    Weisshaar S, Litschauer B, Reichardt B, Gruber F, Leitner S, Sibinovic S, Kossmeier M, Wolzt M.
    Rheumatol Int; 2022 Sep 01; 42(9):1597-1603. PubMed ID: 35589988
    [Abstract] [Full Text] [Related]

  • 8. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
    Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, Kim SC.
    Circulation; 2018 Sep 11; 138(11):1116-1126. PubMed ID: 29899013
    [Abstract] [Full Text] [Related]

  • 9. Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study.
    Tong Q, Du Y, Cui R, Chen M, Wang SI, Wei JC, Dai SM.
    Drugs; 2022 Dec 11; 82(18):1717-1726. PubMed ID: 36479686
    [Abstract] [Full Text] [Related]

  • 10. `Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea.
    Jeong H, Choi E, Suh A, Yoo M, Kim B.
    Rheumatol Int; 2023 Feb 11; 43(2):265-281. PubMed ID: 36346443
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease.
    Lee JS, Won J, Kwon OC, Lee SS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S.
    J Rheumatol; 2019 May 11; 46(5):527-531. PubMed ID: 30442825
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat.
    Shin A, Choi SR, Han M, Ha YJ, Lee YJ, Lee EB, Kang EH.
    Semin Arthritis Rheum; 2022 Oct 11; 56():152080. PubMed ID: 35973263
    [Abstract] [Full Text] [Related]

  • 16. [Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
    Alten R, Mischkewitz M, Nitschmann S.
    Internist (Berl); 2020 May 11; 61(5):530-532. PubMed ID: 32130437
    [No Abstract] [Full Text] [Related]

  • 17. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    Xu S, Liu X, Ming J, Chen S, Wang Y, Liu X, Liu H, Peng Y, Wang J, Lin J, Ji H, Liu B, Lu Y, Liu P, Zhang Y, Ji Q.
    Int J Rheum Dis; 2015 Jul 11; 18(6):669-78. PubMed ID: 26013187
    [Abstract] [Full Text] [Related]

  • 18. Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data.
    Singh JA, Cleveland JD.
    Ann Rheum Dis; 2020 Apr 11; 79(4):529-535. PubMed ID: 32024648
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH, Sohn M, Han N, Cho YS, Kim YS, Oh JM.
    Int J Clin Pharmacol Ther; 2018 Jul 11; 56(7):321-327. PubMed ID: 29750634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.